BioSolution Signs Exclusive Sales Contract for 'CatiLife' Worth 3.5 Billion KRW
[Asia Economy Reporter Geum Bo-ryeong] BioSolution announced on the 7th that it has signed an exclusive domestic sales and supply contract with Korea Mundipharma for the autologous cartilage-derived chondrocyte therapy 'Cartilife' worth 3.5 billion KRW.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Iranian Stock Market Reopens After 80 Days Following War
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The contract amount is 33.25% of the sales revenue based on 2018.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
